期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

骨性关节炎生物学标记物Ⅱ型胶原羧基前肽的研究进展

RESEARCH PROGRESS OF C TERMINAL PROPEPTIDE OF COLLAGEN TYPE Ⅱ
原文传递
导出
摘要 目的综述骨性关节炎(osteoarthritis,OA)生物学标记物Ⅱ型胶原羧基前肽(Cterminal propeptide of collagen typeⅡ,CTX-Ⅱ)的研究进展。方法广泛查阅近年关于CTX-Ⅱ的文献,并对其进行分析。结果 CTX-Ⅱ是目前用于检测OA的生物学标记物之一,其研究最为广泛。CTX-Ⅱ在OA早期诊断、预测病情进展与评价治疗效果方面发挥着重要作用。结论单一检测CTX-Ⅱ不能准确地早期诊断并预测OA病情进展,需要结合其他标记物或检查方法。 Objective To review the research progress of C terminal propeptide of collagen type II（CTX-II）,a osteoarthritis（OA） biomarker.Methods Domestic and international literature about CTX-II was reviewed extensively and summarized.Results CTX-II is investigated broadly and has the best performance of all currently available biomarkers.CTX-II is a truly useful biomarker for early diagnosis,prognosis,and measurement of treatment response in OA.Conclusion Single CTX-II may be not sufficient for early diagnosis and prognosis of OA,so a combination of CTX-II and other biomarkers or diagnosis methods is needed.
作者 白伦浩 王瑜 巴根
机构地区 中国医科大学附属盛京医院脊柱关节骨科
出处 《中国修复重建外科杂志》 CAS CSCD 北大核心 2011年第1期66-69,共4页 Chinese Journal of Reparative and Reconstructive Surgery
关键词 Ⅱ型胶原羧基前肽 骨性关节炎 生物学标记物 C terminal propeptide of collagen type II Osteoarthritis Biomarker
分类号 R684 [医药卫生—骨科学]
  • 相关文献

参考文献29

  • 1van Spil WE, DeGroot J, Lems WF, et al. Serum and urinary biochemical markers for knee and hip-osteoarthritis: a systematic review apply ing the consensus BIPED criteria. Osteoarthritis Cartilage, 2010, 18(5) 605-612.
  • 2Christgau S, Garnero P, Fledelius C, et al. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone, 2001, 29(3): 209-215.
  • 3Kong SY, Stabler TV, Criscione LG, et al. Diurnal variation of serum and urine biomarkers in patients with radiographic knee osteoarthritis. Arthritis Rheum, 2006, 54(8): 2496-2504.
  • 4Karsdal MA, Byrjalsen I, Leeming DJ, et al. Tibolone inhibits bone resorption without secondary positive effects on cartilage degradation. BMC Musculoskelet Disord, 2008, 18(9): 153.
  • 5Sarukawa J, Takahashi M, Doi M, et al. A longitudinal analysis of urinary biochemical markers and bone mineral density in STR/Ort mice as a model of spontaneous osteoarthritis. Arthritis Rheum, 2010, 62(2): 463-471.
  • 6Appleton CT, McErlain DD, Pitelka V, et al. Forced mobilization accelerates pathogenesis: characterization of a preclinical surgical model of osteoarthritis. Arthritis Res Ther, 2007, 9( 1): R13.
  • 7Huebner JL, Williams JM, Deberg M, et al. Collagen fibril disruption occurs early in primary guinea pig knee osteoarthritis. Osteoarthritis Cartilage, 2010, 18(3): 397-405.
  • 8Dam EB, Byrjalsen I, Karsdal MA, et al. Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Osteoarthritis Cartilage, 2009, 17(3): 384-389.
  • 9Meulenbelt I, Kloppenburg M, Kroon HM, et al. Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. Ann Rheum Dis, 2006, 65(3): 360-365.
  • 10Bruyere O, Collette J, Kothari M, et al. Osteoarthritis, magnetic resonance imaging, and biochemical markers: a one year prospective study. Ann Rheum Dis, 2006, 65(8): 1050-1054.

二级参考文献33

  • 1Oldberg A, Antonsson P, Lindblom K, et al. COMP (cartilage oligomeric matrix protein) is structurally related to the thrombospondins. J Biol Chem, 1992, 267(31): 22346-22350.
  • 2Aigner T, McKenna L. Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Mol Life Sci, 2002, 59(1): 5-18.
  • 3Saxne T, Heinegard D. Cartilage oligomeric matrix protein: a novel marker of cartilage turnover detectable in synovial fluid and blood. Br J Rheumatol, 1992, 31(9): 583-591.
  • 4Geng H, Carlsen S, Nandakumar KS, et al. Cartilage oligomeric matrix protein deficiency promotes early onset and the chronic development of collagen-induced arthritis. Arthritis Res Ther, 2008, 10(6): 134.
  • 5Hashimoto Y, Tomiyama T, Yamano Y, et al. Mutation (D472Y) in the type 3 repeat domain of cartilage oligomeric matrix protein affects its earl), vesicle trafficking in endoplasmic reticulum and induces apoptosis. Am J Pathol, 2003, 163(1): 101-110.
  • 6Gagarina V, Carlberg AL, Pereira-Mouries L, et al. Cartilage oligomeric matrix protein protects cells against death by elevating members of the lAP family of survival proteins. J Biol Chem, 2008, 283(1): 648-659.
  • 7Wislowska M, Jablofiska B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol, 2005, 24(3): 278-284.
  • 8Garnero P, Piperno M, Gineyts E, et al. Cross sectional evaluation of biochemical markers of bone, cartilage, and synodal tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann Rheum Dis, 2001, 60(6): 619-626.
  • 9Hunter DJ Li J, LaValley M, et aL Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther, 2007, 9(5): 108.
  • 10Jansen NW, Roosendaal G, Lundin B, et al. The combination of the biomarkers urinary C-terminal telopeptide of type Ⅱ collagen, serum cartilage oligomeric matrix protein, and serum chondroitin sulfate 846 reflects cartilage damage in hemophilic arthropathy. Arthritis Rheum, 2009, 60(1): 290-298.

共引文献7

中国修复重建外科杂志
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部